CHF Solutions Inc (NASDAQ:CHFS) has coverage initiated with a Buy rating

Analyst Ratings For CHF Solutions Inc (NASDAQ:CHFS)

Story continues below

Today, Dawson James initiated coverage on CHF Solutions Inc (NASDAQ:CHFS) with a Buy.

There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on CHF Solutions Inc (NASDAQ:CHFS) is Buy with a consensus target price of N/A per share, a potential N/A.

Some recent analyst ratings include

  • 8/28/2018-CHF Solutions Inc (NASDAQ:CHFS) has coverage initiated with a Buy rating
  • 6/29/2017-CHF Solutions Inc (NASDAQ:CHFS) has coverage initiated with a Buy rating and $65.00 price target

Recent Insider Trading Activity For CHF Solutions Inc (NASDAQ:CHFS)
CHF Solutions Inc (NASDAQ:CHFS) has insider ownership of 3.50% and institutional ownership of 20.58%.

  • On 8/10/2018 Gregory D. Waller, Director, sold 72 with an average share price of $1.03 per share and the total transaction amounting to $74.16.
  • On 7/3/2018 John L. Erb, CEO, bought 23,584 with an average share price of $2.12 per share and the total transaction amounting to $49,998.08.
  • On 10/12/2017 Ki Yong Choi, Major Shareholder, bought 61,645 with an average share price of $0.52 per share and the total transaction amounting to $32,055.40.
  • On 9/13/2017 Ki Yong Choi, Major Shareholder, bought 78,211 with an average share price of $0.64 per share and the total transaction amounting to $50,055.04.
  • On 11/28/2016 John L Erb, CEO, bought 80,000 with an average share price of $0.22 per share and the total transaction amounting to $17,600.00.
  • On 3/16/2016 John L Erb, CEO, bought 2,500 with an average share price of $0.91 per share and the total transaction amounting to $2,275.00.
  • On 3/15/2016 John L Erb, CEO, bought 16,000 with an average share price of $0.91 per share and the total transaction amounting to $14,560.00.

About CHF Solutions Inc (NASDAQ:CHFS)
CHF Solutions, Inc., an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. The company focuses on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. It offers Aquadex FlexFlow consoles and the related disposable products in Singapore and Hong Kong. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.

Recent Trading Activity for CHF Solutions Inc (NASDAQ:CHFS)
Shares of CHF Solutions Inc closed the previous trading session at 1.18 up +0.0100 0.85% with 1.23 shares trading hands.

An ad to help with our costs